Hospitals | Molecular Health

Hospitals

Integrating precision medicine into everyday oncological clinical practice

How to make your molecular tumor boards even more efficient with the help of Molecular Health Guide (MH Guide)

Hospitals

Integrating precision medicine into everyday oncological clinical practice

How to make your molecular tumor boards even more efficient with the help of Molecular Health Guide (MH Guide)

Holistic analyses via “omics” technologies

Establishing molecular tumor boards at hospitals is an important step towards applied precision medicine. Another key development is the diagnostic options which ‘omics’ technologies now offer us when it comes to understanding a disease more thoroughly, integrating these options into tumor boards, and making full use of the relevant technologies.

 

The complexity of these kinds of holistic approaches inevitably ties up resources and capacities in a way that does not make everyday clinical work any easier for those involved, and it is already multifaceted enough. This means it is all the more important to select technologies which contribute to efficiency and precision. 

Molecular tumor boards as a key step towards applied precision medicine in hospitals

Precision medicine and personalized medicine are both buzzwords which describe the paradigm shift in medical science today. The efficacy and quality of patient treatment will continue to be optimized thanks to the development of new diagnostic strategies and the use of customized treatment. At the same time, adverse effects will be reduced, which over time will increase cost-effectiveness.

 

The greatest obstacle along the path towards personalized medicine is not so much the cost, as is often assumed. Instead, it is the full utilization of all of the patient data collected — from the clinical medical history to the highly complex “omics” data sets from tumor tissues and their interdisciplinary assessment in boards. 

Logo of MH Mendel
CE Logo
Logo of IVD
TÜV Logo

Create a precision medicine center of excellence

MH Guide is an end-to-end software solution for hospitals and clinics. It provides assistance in making therapeutic decisions in clinical oncology. The software interprets
sequencing data from the DNA of the patient’s tumor and generates interactive medical
reports including data on drug efficacy, adverse effects, drug interactions and tolerability so that potentially dangerous options can be ruled out. The outcome enables physicians to make customized therapeutic recommendations and rely upon a molecular-based and precise form of support in clinical findings.

Cloud Icon

Simple cloud-based portal

Quick login & access to latest platform version

Speed Icon

Delivers results quickly

Industry-leading speed for clinical annotation and report generation

Simple Icon

Simple

Simple upload of data file via sFTP secure procedure

Trust Icon

Trustworthy

Our annotations undergo a rigorius review process

Secure Icon

Secure

HIPPA compliant and industry-standard data encryption

Scale Icon

Scalable

Review as many variants as you deem useful

Platform Icon

Platform agnostic

Accepts standard file formats (like VCF or XML), regardless of analytical methods

Affordable Icon

Affordable

Individual and volume pricing available

Improve clinical outcomes continuously

Because EMR data contains patterns and insights that can improve patient safety, clinical outcomes and quality metrics, being able to easily access and harness your own EMR patient data can change how your institution approaches healthcare. Adding a molecular data layer to your clinical decision processes could bring you even closer to precision medicine. The cycle of identifying new insights can be iteratively incorporated into your treatment plans, protocols and enhance your databases.

How your hospital can benefit from MH Guide

Creates cost-efficient and highly precise reports for your tumor board and direct routes to efficacious drug-based cancer treatment for your patients

 

Prevents greater incidence of adverse effects and unnecessary treatments

 


Saves significant amounts of time for doctors making therapeutic decisions



Molecular Health Button
Molecular Health Button
Molecular Health Button

Offers seamless integration of the process into your diagnostic procedures



Facilitates handling larger numbers of cases per month



 

Mine, query and extract insights from clinical and molecular data on drugs, diseases and outcomes and enhance your EMRs, Clinical Trial data, or molecular data from biological analyses

 

Molecular Health Button
Molecular Health Button
Molecular Health Button

How your hospital can benefit from COPE

Creates cost-efficient and highly precise reports for your tumor board and direct routes to efficacious drug-based cancer treatment for your patients

Molecular Health Button

Prevents greater incidence of adverse effects and unnecessary treatments

 

Molecular Health Button

Saves significant amounts of time for doctors making therapeutic decisions

 

Molecular Health Button

Offers seamless integration of the process into your diagnostic procedures

 

Molecular Health Button

Facilitates handling larger numbers of cases per month 

 

Molecular Health Button

Mine, query and extract insights from clinical and molecular data on drugs, diseases and outcomes and enhance your EMRs, Clinical Trial data, or molecular data from biological analyses

Molecular Health Button

Our hospital partners

Logo of Uni Klinikum Heidelberg
Kliniken Essen-Mitte
Logo of Karolinska Institutet
Universität Greifswald
Logo of UKE Hamburg
Universitätsklinikum Düsseldorf
Logo of Charité
Uniklinikum Essen
Logo of Hochtaunus Kliniken
Uniklinikum Tübingen

Our powerful applications for treatment decision support


Molecular Health Guide (MH Guide) identifies safe and effective therapies for patients by analyzing the molecular profile. It matches detected mutations to the world’s knowledge in the field of oncology and hereditary diseases and helps medical experts to create a patient-specific clinical report. MH Guide is an IVD registered in the EU.


 

Read more


Molecular Health Guide Mendel (MH Mendel)
supports human geneticists to identify clinically significant genetic variants and create a diagnostic report for individual patients.   

MH Mendel is part of the Molecular Health Guide (MH Guide) solution which is an IVD registered in the EU. 





Read more

Logo of MH BRCA


Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants associated with hereditary breast and ovarian cancer (HBOC) syndrome from NGS-based assessment of BRCA1 and BRCA2 and other HBOC related genes. MH BRCA is part of the Molecular Health Guide (MH Guide) solution which is an IVD registered in the EU.



Let’s talk about how our technology can work for you

To find out more, you can call our customer care team or help desk or send us an e-mail. We would be delighted to provide you with more information or answer your questions.


EU: +49 6221 43851-150
E-Mail: CustomerCareEU@molecularhealth.com